NASDAQ
Cynata Therapeutics Limited (CYYNF) has a price/sales ratio of 13.22x as of Friday, May 22, 2026. This represents a 53.64% decrease compared to its 12-month average of 28.50x. The price-to-sales ratio evaluates a company's stock price relative to its revenue, useful for valuing companies with little or no earnings.
No price data available for this timeframe.